Uses of Belsartas 150mg

Belsartas medicine 150mg is prepared in the form of film-coated tablets, with the main ingredient being Irbesartan 150mg and other excipients just enough for 1 tablet.
Irbesartan belongs to a group of selective antagonists on angiotensin II receptors, has the effect of inactivating angiotensin II receptors, inhibiting the renin - angiotensin system thereby causing vasodilation, lowering blood pressure.

Belsartas medicine 150mg is used in the treatment of the following cases:
Idiopathic hypertension Kidney disease in patients with type 2 diabetes mellitus with hypertension Do not use Belsartas 150mg drug in the following cases:
Hypersensitive people with Irbesartan or any of the ingredients in it. Pregnant women in the second and third trimesters of pregnancy due to fetal toxicity (decreased renal function, oligohydramnios, delayed ossification of the skull) and neonatal toxicity (renal failure, hyperkalemia, lower blood pressure).

Dosage depends on each subject:
The recommended dose for initiation and maintenance of treatment is 150mg/time/day, regardless of meals. A dose of 300 mg/day may be used or in combination with other antihypertensive agents in patients whose blood pressure is not controlled at a dose of 150 mg. In particular, the addition of a diuretic such as hydrochlorothiazide will increase the therapeutic effect of Belsartas. In patients with type 2 diabetes and hypertension: initiate treatment with 150 mg once daily and may adjust the dose to 300 mg once daily in the treatment of renal disease. No dose adjustment is required in patients with renal impairment, but a lower starting dose (75 mg) may be used in hemodialysis patients. No dose adjustment is required in patients with mild to moderate hepatic impairment, and clinical data are not available for use in patients with severe hepatic impairment. A starting dose of 75 mg is recommended in people > 75 years of age. The safety and effectiveness of the drug when used in children < 18 years of age have not been established, so its use is not recommended in this population.

When using Belsartas, you may experience some of the following undesirable effects:
Hyperkalemia Elevated CK enzymes (not related to musculoskeletal diseases) Fatigue, headache, dizziness, orthostatic hypotension , fast heartbeat Cough, chest pain Digestive disorders: heartburn, nausea, vomiting, diarrhea Musculoskeletal pain During the use of Belsartas, if you encounter any serious side effects, the patient should contact the patient. Stop taking the drug and contact the treating doctor or immediately go to a medical facility for timely treatment.

When using concomitantly Belsartas may cause interactions with some of the following drugs:
When combined with other antihypertensive drugs may increase the antihypertensive effect of Irbesartan. However, Belsartas can be used safely when co-administered with antihypertensive agents such as beta-blockers, calcium channel blockers, and thiazide diuretics. Prior use of high-dose diuretics may cause volume depletion and the risk of hypotension when initiating Belsartas. Potassium-sparing diuretics and potassium supplements: Concomitant use of potassium-sparing diuretics, potassium supplements, and drugs that increase blood potassium (such as heparin) may lead to hyperkalemia. Therefore, the combination of these drugs is not recommended. Concomitant use with non-steroidal anti-inflammatory drugs may reduce the antihypertensive effect of Belsartas, and increase the risk of impaired renal function, renal failure and hyperkalemia, especially in those with a history of pre-existing renal impairment. Therefore, function should be closely monitored and caution should be exercised when using these two classes of drugs together. Concomitant use with Lithium is not recommended, as it may cause an increase in serum lithium concentrations.

When using Belsartas, caution should be exercised in the following cases:
Periodic monitoring of serum creatinine and potassium levels is recommended when using Belsartas in patients with renal failure. Use with caution in patients with aortic stenosis, mitral stenosis and hypertrophic obstructive cardiomyopathy. Use with caution in patients with hypovolemia or hyponatremia. Belsartas is not recommended for patients with primary hyperaldosteronism. Not recommended for use in pregnant women in the first trimester of pregnancy, contraindicated in the second and third trimesters of pregnancy. The drug is not recommended for use in lactating women, due to insufficient data on its safety. When using the drug can cause dizziness, headache, so be careful when driving or operating machinery. In addition to the above information, if during use you have any questions about Belsartas 150mg, please contact your treating doctor for advice and answers.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.